Re-engineered p53-based therapies tailored to the specific patient’s disease and delivered with improved vectors, in tandem with combination therapies when needed, hold great therapeutic potential for the treatment of HGSOC and ovarian cancer in general. Here, TP53 is linked to ovarian carcinoma.